April 22nd 2024
The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Natural Killer Cells Could Bypass Limitations of CAR T Cells in CLL, Expert Says
September 27th 2018In an interview with <em>Targeted Oncology</em>, Katy Rezvani, MD, discussed the potential she sees with CAR NK cells. She also highlighted some of the challenges with both CAR T-cell therapy in patients with CLL, as well as challenges to overcome with CAR NK cells in this patient population.
Read More
Duvelisib Granted FDA Approval for CLL and Follicular Lymphoma
September 25th 2018Duvelisib (Copiktra) has been approved by the FDA for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed/refractory follicular lymphoma. Both indications are for the treatment of patients who have received at least 2 prior therapies.
Read More
EU Panel Supports Approval of Venetoclax/Rituximab Combo in Relapsed/Refractory CLL
September 24th 2018Based on data from the phase III MURANO trial, the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of venetoclax for patients with chronic lymphocytic leukemia who have received at least 1 previous therapy. AbbVie, a co-developer of venetoclax with Roche, announced the CHMP’s decision in a news release.
Read More
Expert Highlights Quizartinib Benefit for Patients With FLT3-ITD+ Relapsed/Refractory AML
September 20th 2018In an interview with <em>Targeted Oncology</em>, Jorge E. Cortes, MD, discussed the results from the QuANTUM-R trial, as well as some other studies investigating the use of quizartinib in different patient populations in AML.
Read More
Adding the combination of venetoclax (Venclexta) and navitoclax (ABT-263) to chemotherapy induced an objective response rate of 66.7% in adults with relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma, according to results from a small phase I study presented at the 2018 SOHO Annual Meeting.
Read More
Moxetumomab Pasudotox Approved by FDA for Treatment of Hairy Cell Leukemia
September 13th 2018Moxetumomab pasudotox has been approved by the FDA for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least 2 prior lines of therapy, including treatment with a purine nucleoside analog.
Read More
Venetoclax CLL Label Updated by FDA to Include MRD Data
September 13th 2018Minimal residual disease data from the phase III MURANO trial has been added to the label for venetoclax (Venclexta) by the FDA for its approved use in combination with rituximab (Rituxan) for previously-treated patients with chronic lymphocytic leukemia.
Read More
Lower-intensity Regimen Shows Promise for Older Patients with AML
September 12th 2018Combining cladribine and low-dose cytarabine alternating with decitabine (Dacogen) resulted in high response rates and improved survival compared with currently established low-intensity therapies for patients with acute myeloid leukemia who are older than 60, according to results newly published in <em>Lancet Haematology.</em>
Read More
Dasatinib Application for Pediatric Ph+ ALL Accepted by FDA
August 31st 2018A supplemental biologics license application for dasatinib (Sprycel) for use in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia has been accepted by the FDA.
Read More
Blinatumomab Granted European Approval for Treatment of Pediatric ALL
August 29th 2018Blinatumomab (Blincyto) has been approved by the European Commission for the treatment of pediatric patients with Philadelphia chromosome–negative, CD19-positive B-cell precursor acute lymphoblastic leukemia that is refractory or in relapse after receiving at least 2 prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation
Read More
Tisagenlecleucel Granted Approval in Europe for DLBCL, ALL
August 27th 2018Tisagenlecleucel has gained approval from the European Commission as a treatment for adult patients with diffuse large B-cell lymphoma that is relapsed or refractory after 2 or more lines of systemic therapy, or patients up to 25 years of age with B-cell acute lymphoblastic leukemia that is refractory, in relapse posttransplant, or in second or later relapse.
Read More
Lead-In Treatment to Reduce Tumor Lysis Syndrome Risk in CLL
August 21st 2018Kerry Rogers, MD, assistant professor at The Ohio State University Comprehensive Cancer Center, discusses a short-term treatment strategy for reducing tumor burden and the risk for tumor lysis syndrome in patients with chronic lymphocytic leukemia.
Watch
Guadecitabine Misses Phase III Endpoints in Frontline AML
August 3rd 2018Guadecitabine failed to improve complete response rate and overall survival in treatment-naïve adult patients with AML who are not candidates for intensive induction chemotherapy, missing the coprimary endpoints of the phase III ASTRAL-1, according to Astex Pharmaceuticals and Otsuka Pharmaceutical.
Read More
Quizartinib Granted Breakthrough Therapy Designation by FDA for FLT3-ITD+ AML
August 1st 2018Quizartinib has been granted a breakthrough therapy designation by the FDA for the treatment of adult patients with relapsed/refractory <em>FLT3</em>-ITD–positive acute myeloid leukemia.
Read More
Complications With CAR T Cells in Chronic Lymphocytic Leukemia
July 31st 2018Susan M. O'Brien, MD, associate director for clinical sciences at UC Irvine Health, shares her insights on why CAR T cells are not as successful in chronic lymphocytic leukemia as compared to lymphoma or acute lymphocytic leukemia. She also discusses what she believes must change in order for this therapy to move up in the treatment landscape for CLL.
Watch